# FibroGen

Source: https://onco.cc/companies/fibrogen/  
OnCo record `fibrogen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A fibrosis-focused biotech whose anti-CTGF antibody pamrevlumab failed phase 3 trials in pancreatic cancer and in lung fibrosis.

## Summary

FibroGen, listed on Nasdaq, built its pipeline on connective tissue growth factor biology and on the anaemia drug roxadustat. Pamrevlumab was its oncology bet, tested in locally advanced pancreatic cancer in the LAPIS trial and in a Precision Promise arm; both were negative in 2024, and the programme was discontinued.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- HQ: San Francisco, California, United States
- Type: biotech
- Website: https://www.fibrogen.com

## Sources

- Official website: https://www.fibrogen.com
- Wikipedia: https://en.wikipedia.org/wiki/FibroGen

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Pamrevlumab](https://onco.cc/drugs/pamrevlumab/)
- trials: [Precision Promise](https://onco.cc/trials/precision-promise/)

---
JSON: https://onco.cc/api/v1/entities/fibrogen.json